Will Degrader-Antibody Conjugates Challenge Traditional ADCs?

Roche has committed $20 million upfront to expand its decade-long partnership with C4 Therapeutics, pivoting from traditional protein degraders to degrader-antibody conjugates (DACs) that combine targeted delivery with protein elimination. The deal grants Roche exclusive global rights to develop DACs using C4's TORPEDO platform, with C4 eligible for up to $2.8 billion in development and commercial milestones across multiple programs.

The collaboration represents a strategic shift toward addressing undruggable proteins through engineered degradation rather than inhibition. While antibody-drug conjugates delivered $8.2 billion in sales for Roche in 2025, DACs promise broader target coverage by eliminating proteins entirely rather than blocking their function. C4's platform combines monoclonal antibodies with heterobifunctional molecules that recruit the cell's natural protein disposal system, potentially accessing the 80% of proteins considered undruggable by conventional small molecules.

The expanded partnership builds on Roche's existing relationship with C4, which began in 2016 and has already advanced multiple degrader programs through preclinical development. C4 will lead discovery and early development while Roche handles clinical advancement and commercialization for selected DAC candidates.

The Technical Challenge Behind DACs

Degrader-antibody conjugates face unique engineering constraints compared to traditional ADCs. While cytotoxic ADCs rely on broad cellular toxicity once internalized, DACs must maintain the molecular machinery needed for targeted protein degradation within specific subcellular compartments.

C4's TORPEDO platform addresses these challenges through optimized linker chemistry and degrader design. The system uses cleavable linkers that release active degraders following antibody internalization, allowing the heterobifunctional molecules to recruit E3 ubiquitin ligases and target proteins into proximity. This process requires careful optimization of degrader concentration, linker stability, and subcellular localization to achieve effective protein elimination without off-target effects.

Early preclinical data suggest DACs can achieve superior therapeutic windows compared to traditional degraders by concentrating active compounds within target cells. However, the approach faces technical hurdles including limited tissue penetration of large antibody constructs and potential immunogenicity from novel linker-degrader combinations.

Market Positioning Against Established ADCs

The DAC market enters a crowded field dominated by Roche's own ADC portfolio, including Kadcyla ($2.1 billion in 2025 sales) and Polivy ($850 million). However, DACs target a fundamentally different mechanism, potentially accessing protein targets beyond the reach of traditional cytotoxic payloads.

Industry analysts project the global ADC market will reach $35 billion by 2030, with next-generation formats like DACs capturing increasing share. Key advantages include broader target accessibility and potentially reduced resistance mechanisms compared to cytotoxic ADCs, which often face efflux pump-mediated resistance.

C4 Therapeutics competes directly with Arvinas and Kymera Therapeutics in the protein degrader space, though the DAC format provides differentiation through targeted delivery. The company's existing pipeline includes CFT7455, a IKZF1/3 degrader in Phase 1 trials for multiple myeloma, demonstrating clinical validation of its degrader chemistry.

Strategic Implications for Protein Degradation

Roche's investment signals growing confidence in degrader modalities beyond traditional small molecule approaches. The pharmaceutical industry has invested over $3 billion in protein degrader companies since 2020, with most focus on oral degraders rather than antibody conjugates.

The partnership provides C4 with significant validation and financial backing to advance DAC technology while allowing Roche to hedge against potential displacement of its ADC franchise. For the broader synthetic biology ecosystem, DACs represent convergence between engineered biologics and chemical degraders, requiring sophisticated design of both antibody and small molecule components.

Success in DACs could accelerate development of other targeted protein elimination approaches, including engineered cellular systems for therapeutic protein degradation. However, the complexity of optimizing both antibody and degrader components simultaneously presents significant technical risks that may limit near-term clinical translation.

Key Takeaways

• Roche commits $20M upfront for exclusive DAC rights using C4's TORPEDO platform, with $2.8B in potential milestones
• DACs combine antibody targeting with protein degradation, potentially accessing undruggable proteins beyond traditional ADC reach
• Technical challenges include optimizing degrader delivery, linker stability, and subcellular localization for effective protein elimination
• Market entry faces competition from Roche's own $8.2B ADC portfolio but targets different mechanism and broader protein coverage
• Partnership represents strategic hedge for Roche while providing C4 validation in crowded $3B protein degrader investment landscape

Frequently Asked Questions

What makes degrader-antibody conjugates different from traditional ADCs? DACs eliminate target proteins through the cell's natural degradation machinery rather than delivering cytotoxic payloads. This allows targeting of previously undruggable proteins that cannot be effectively inhibited by small molecules or blocked by traditional antibody mechanisms.

How large is C4's potential payout from the Roche partnership? C4 is eligible for up to $2.8 billion in development and commercial milestones across multiple DAC programs, plus the $20 million upfront payment. The company retains rights to lead discovery and early development while Roche handles clinical advancement.

What technical challenges do DACs face compared to regular protein degraders? DACs must maintain degrader activity following antibody internalization while ensuring proper subcellular localization for target protein engagement. This requires optimized linker chemistry, degrader stability, and careful management of intracellular concentrations to achieve effective protein elimination.

Which companies are leading the protein degrader market? Arvinas leads with the most advanced clinical pipeline, followed by Kymera Therapeutics and C4 Therapeutics. The broader market has attracted over $3 billion in investment since 2020, though most focus on oral degraders rather than antibody conjugates.

How does this partnership affect Roche's existing ADC business? The DAC partnership represents a strategic hedge that could expand Roche's addressable target space while potentially cannibalizing traditional ADC applications. Roche's existing ADC portfolio generated $8.2 billion in 2025 sales, making this both a growth opportunity and portfolio risk management strategy.